Deutsche Bank AG Raises Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 252,501 shares of the company's stock after purchasing an additional 27,282 shares during the period. Deutsche Bank AG owned approximately 0.25% of Intellia Therapeutics worth $2,944,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Barclays PLC grew its position in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after purchasing an additional 44,022 shares during the last quarter. ARK Investment Management LLC grew its position in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the last quarter. SG Americas Securities LLC grew its position in Intellia Therapeutics by 85.7% during the 4th quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after purchasing an additional 20,694 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Intellia Therapeutics during the 4th quarter worth $4,793,000. Finally, Baker BROS. Advisors LP purchased a new position in Intellia Therapeutics during the 4th quarter worth $7,510,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Down 4.9%

Shares of NASDAQ NTLA opened at $9.20 on Thursday. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18. The firm has a 50-day moving average price of $7.99 and a 200 day moving average price of $10.67. The stock has a market capitalization of $952.96 million, a price-to-earnings ratio of -1.69 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. During the same quarter last year, the business posted ($1.12) earnings per share. The business's revenue was down 42.6% compared to the same quarter last year. Equities research analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on NTLA shares. Guggenheim lowered their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Chardan Capital restated a "buy" rating and issued a $68.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 9th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley cut shares of Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and reduced their target price for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Citigroup reduced their target price on shares of Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $36.90.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.